View in EDS

CONGENITAL MUSCULAR DYSTROPHIES: P.329CALLISTO: a phase I open-label, sequential group, cohort study of pharmacokinetics and safety of omigapil in LAMA2 and COL6-related dystrophy patients.

Saved in:
Bibliographic Details
Title: CONGENITAL MUSCULAR DYSTROPHIES: P.329CALLISTO: a phase I open-label, sequential group, cohort study of pharmacokinetics and safety of omigapil in LAMA2 and COL6-related dystrophy patients.
Authors: Foley, A.R.1, Leach, M.1, Averion, G.1, Hu, Y.1, Yun, P.1, Neuhaus, S.1, Saade, D.1, Arevalo, C.1, Fink, M.1, DeCoster, J.1, Mendoza, C.1, Mayer, O.2, Hausmann, R.3, Petraki, D.3, Cheung, K.4, Bönnemann, C.1
Source: Neuromuscular Disorders. Oct2018:Supplement 2, Vol. 28, pS129-S130. 1p.
Database: Academic Search Ultimate
Description
ISSN:09608966
DOI:10.1016/j.nmd.2018.06.377